These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 2573424

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
    Paterson MC, Dietrich KD, Danyluk J, Paterson AH, Lees AW, Jamil N, Hanson J, Jenkins H, Krause BE, McBlain WA.
    Cancer Res; 1991 Jan 15; 51(2):556-67. PubMed ID: 1670762
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Proto-oncogene abnormalities in human breast cancer: c-ERBB-2 amplification does not correlate with recurrence of disease.
    Zhou DJ, Ahuja H, Cline MJ.
    Oncogene; 1989 Jan 15; 4(1):105-8. PubMed ID: 2915899
    [Abstract] [Full Text] [Related]

  • 13. HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis.
    Tiwari RK, Borgen PI, Wong GY, Cordon-Cardo C, Osborne MP.
    Anticancer Res; 1992 Jan 15; 12(2):419-25. PubMed ID: 1349794
    [Abstract] [Full Text] [Related]

  • 14. Int-2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB-2/neu amplifications in primary human breast cancer.
    Champème MH, Bièche I, Hacène K, Lidereau R.
    Mod Pathol; 1994 Dec 15; 7(9):900-5. PubMed ID: 7892157
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. HER-2/neu amplification predicts poor survival in node-positive breast cancer.
    Borg A, Tandon AK, Sigurdsson H, Clark GM, Fernö M, Fuqua SA, Killander D, McGuire WL.
    Cancer Res; 1990 Jul 15; 50(14):4332-7. PubMed ID: 1973070
    [Abstract] [Full Text] [Related]

  • 18. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1.
    Tsuda H, Hirohashi S, Shimosato Y, Hirota T, Tsugane S, Yamamoto H, Miyajima N, Toyoshima K, Yamamoto T, Yokota J.
    Cancer Res; 1989 Jun 01; 49(11):3104-8. PubMed ID: 2566377
    [Abstract] [Full Text] [Related]

  • 19. Proto-oncogene amplification and human breast tumor phenotype.
    Adnane J, Gaudray P, Simon MP, Simony-Lafontaine J, Jeanteur P, Theillet C.
    Oncogene; 1989 Nov 01; 4(11):1389-95. PubMed ID: 2554239
    [Abstract] [Full Text] [Related]

  • 20. Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up.
    Thor AD, Schwartz LH, Koerner FC, Edgerton SM, Skates SJ, Yin S, McKenzie SJ, Panicali DL, Marks PJ, Fingert HJ.
    Cancer Res; 1989 Dec 15; 49(24 Pt 1):7147-52. PubMed ID: 2573426
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.